license AND SERVICES AGREEMENTLicense and Services Agreement • June 29th, 2022 • Jaguar Health, Inc. • Pharmaceutical preparations • California
This LICENSE AND Services AGREEMENT (this “Agreement”) is made effective as of June 28, 2022 (the “Effective Date”) by and between Jaguar Health, Inc., a Delaware corporation (“Licensor”), SynWorld Technologies Corporation, a corporation duly incorporated under the laws of Canada (“Licensee”), solely for purposes of Sections 10.4 (Representations and Warranties of Licensee, Licensee Guarantor and Parent), 11.3 (Indemnification by Licensee Guarantor and Parent) and 14.13 (Guaranty), C&E Telecom, LTD, a company organized under the laws of the British Virgin Islands (“Licensee Guarantor”), and, solely for purposes of Sections 10.4 (Representations and Warranties of Licensee, Licensee Guarantor and Parent) and 11.3 (Indemnification by Licensee Guarantor and Parent), Tao Wang, an individual (“Parent”). Licensor and Licensee and, solely for purposes of Article 11 (Indemnification; Liability; Insurance), Licensee Guarantor and Parent are referred to in this Agreement individually as a “Party”
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion,...Exclusive License and Commercialization Agreement • June 29th, 2022 • Jaguar Health, Inc. • Pharmaceutical preparations
SAN FRANCISCO, CA / June 29, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the company has entered an exclusive license and services agreement with Ontario, Canada-based SynWorld Technologies Corporation (SynWorld) for the treatment of diarrhea in dogs in the China market with Jaguar’s Canalevia® (crofelemer delayed-release tablets) prescription drug product.
